Individualizing treatment strategies in the management of metastatic breast cancer

Michael Naughton

Research output: Contribution to journalArticlepeer-review


The treatment of metastatic breast cancer continues to evolve with better understanding of the underlying biology and genetics and newer medications. Although not yet curable, progress is being made with increases in overall median survival. Several new medications are changing the treatment paradigm for advanced disease.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalJournal of Managed Care Medicine
Issue number3
StatePublished - Sep 16 2013


  • A do-trastuzumab emtansine is a new option for HER -2 positive disease
  • E verolimus is a new option in the postmenopausal, estrogen receptor positive patients
  • I n premenopausal and postmenopausal patients with estrogen receptor positive disease, sequential endocrine agents are used until no longer effective
  • Metastatic breast cancer is not curable
  • Treatment is chosen based on tumor biology


Dive into the research topics of 'Individualizing treatment strategies in the management of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this